Introduction
Intramuscular interferon (IFN) beta-1a was first approved for the treatment of relapsing multiple sclerosis (RMS) in 1996, and it has proved effective in reducing relapse rate and disability progression in patients with RMS. 1, 2 Over the past decade, multiple IFN beta-1a biosimilar formulations have been approved to treat RMS, although none have been approved as disease-modifying therapies for RMS in either the European Union or the United States. Currently, over ten different IFN beta-1a biosimilar formulations have been developed and approved to treat RMS in at least ten Asian and Latin American countries. 3 IFN beta-1a biosimilars can vary from their reference proteins by virtue of the cell type in which the proteins are synthesized as well as in the final purification steps. [4] [5] [6] Given the biological complexity of these potential differences, the possibility that small changes in protein structure can have dramatic effects on the immunogenicity of such proteins, including the production of neutralizing antibodies (NAbs), is a particular concern. Similarly, these steps may lead to changes in the stability of the protein and the level of aggregation. The path to approval for biosimilars varies by region, and controlled studies are not always required for biosimilar drug approval or may be of too short a duration to assess the impact of differences in immunogenicity. 5 The lack of these validation studies presents a potential safety issue because NAbs can reduce IFN beta-1a activity, resulting in a diminished clinical response to all IFNs. Thus there is a growing consensus that biosimilar products should be evaluated to determine if they have equivalent immunogenicity, safety, and efficacy to the reference compound. [7] [8] [9] Although European Union regulators recently announced that magnetic resonance imaging (MRI)-based variables may be used for evaluating biosimilars, 10, 11 assessing the clinical efficacy of IFN beta-1a-based therapeutics can be difficult because of the relatively low incidence of relapses, even in placebo-treated RMS patients. For this reason, a variety of biomarkers, including the metabolic factor neopterin, beta-2-microglobulin, and 2′-5′-oligoadenylate synthetase, are routinely used to determine IFN bioactivity. 12 While such biomarkers are not useful measurements of efficacy, they are appropriate for measurements of biological activity. Measuring serum concentrations of neopterin is a common method of assessing IFN beta-1a biological and pharmacodynamic activity. 13 A patient's steady-state serum neopterin concentration is generally elevated while the patient is on IFN beta-1a therapy and typically increases following each IFN beta-1a injection.
14 Thus, it is important to monitor both steady-state neopterin levels and the change induced by a given dose to assess the efficacy of an IFN beta-1a therapy.
The intramuscular IFN beta-1a formulation Avonex ® (Biogen, Cambridge, MA, USA) elicits low immunogenicity, with a persistent NAb rate of 2%-8%, [15] [16] [17] whereas the immunogenicity of the biosimilar drug Jumtab ® (Probiomed, Miguel Hidalgo, Mexico), approved to treat RMS in Mexico, Colombia, and Peru, is unknown. This study was designed to directly compare Avonex and Jumtab, focusing on the incidence of NAbs.
Methods

MATRIX (Measuring neutralizing Antibodies in patients
TReated with Interferon beta-1a IM in MeXico; Clinical Trial NCT01556685) was a multicenter, cross-sectional, retrospective, observational study conducted in Mexico and Colombia. The study protocol included up to 180 retrospectively identified patients (90 per group) who had been treated with either Avonex or Jumtab as their first and only disease-modifying therapy for multiple sclerosis (MS) for 1-3 years, ie, the time when peak antibody titers in NAbpositive individuals are expected. All patients followed the same dosing schedule of once-weekly self-injection. Patients who had previously been treated with immunosuppressive therapy were excluded. There were no limitations on age, Expanded Disability Status Scale (EDSS) score, or other disease parameters as a condition for patient enrollment. The study protocol and informed consent forms were approved by the appropriate institutional review board for each site, and all patients provided written informed consent before entering the study.
The primary endpoint was the frequency of NAb levels .100 tenfold reduction units (TRU) in patients treated exclusively with either Avonex or Jumtab. Secondary endpoints included changes in neopterin levels as a proxy assessment of efficacy and additional measures of safety and tolerability over a 2-year time course, including the frequency of NAb levels .20 TRU and of flu-like symptoms.
The development of NAbs and neopterin induction were assessed in a cross-sectional analysis performed at a subset of preselected study sites. Patient blood samples were collected before IFN beta-1a injection and then sent to a central laboratory for analysis using a commercial luciferase assay. 18 Possible relationships between patient NAb status and drug tolerability/safety were evaluated through a retrospective patient record review by investigators blinded to the patients' therapy. The immunogenicity rate was predetermined to be based on a single assessment and did not require persistence to be deemed positive. NAb levels .100 TRU were considered positive for the primary endpoint evaluation; NAb levels .20 TRU were considered positive for the secondary endpoint evaluation. At a select number of sites, patient blood samples were also collected 48-72 hours post-dose for analysis. The biological response to IFN beta-1a injections was assessed by mean percentage change in serum neopterin levels and by mean pre-versus post-dose concentration difference. Neopterin serum concentrations were measured using a competitive binding enzyme immunoassay (MP Biomedical, Solon, OH, USA), with a quantitation range of 0.906-101 ng/mL and assay precision (percentage coefficients of variability of assay controls) of 8.4%-13.3%. Safety was assessed by adverse events collected during treatment. Relapses and associated outcomes were assessed 
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low immunogenicity but reduced bioavailability of an iFn beta-1a biosimilar based on retrospective review of patient records from 1 to 3 years prior to study enrollment. Summary statistics for relapse-associated outcomes were calculated as the total number of relapses, days of hospitalization, or duration of corticosteroid treatment reported divided by the number of patients reporting the outcome. Data are presented as mean (standard deviation [SD]) and median (range). The Wilcoxon rank sum test was used to determine significance for paired data (not normally distributed), a chi-square test was used for analyses of categorical data, and two-tailed t-tests were used for normally distributed, continuous data.
Results Patients
This study aimed to enroll a total of 180 patients (90 per treatment group). However, a number of external factors in both Mexico and Colombia limited study enrollment, including national government policies dictating pharmacy substitution of branded medications with locally produced biosimilars (Mexico) and the lack of availability of study medications at some local pharmacies. In addition, the inability to confirm that all patients had been treated with only one formulation over the 3-year duration of the study reduced enrollment. Final enrollment was limited to 65 patients whose entire treatment history could be confirmed: 36 patients treated exclusively with Avonex and 29 treated exclusively with Jumtab. The effect of this reduced enrollment on the statistical interpretation of the study results should be considered in subsequent data analysis and is discussed later.
The two patient populations were similar, with the exception that patients on Avonex therapy were significantly younger than those on Jumtab (mean [SD]: 37.1 [9.2] versus 44.6 [11.5] years; P=0.005; Table 1 ). In addition, despite having been diagnosed more recently (1.3 versus 2.9 years earlier; P=0.082), patients in the Avonex group tended to have a higher mean baseline EDSS score (2.2 versus 1.5; P=0.106). The duration (SD) of IFN beta-1a therapy was 24.5 (7.5) months for Avonex and 22.1 (8.1) months for Jumtab (P=0.214). There were no differences between treatment groups in either the time from the first documented clinical event to the start of therapy or the time from the diagnosis of clinically definite MS to the start of IFN beta-1a therapy.
Biomarkers
NAb levels were obtained in 36 Avonex-treated and 29 Jumtab-treated patients. No patients developed NAb levels .100 TRU, and levels of .20-100 TRU were detected in one patient from each treatment group (Table 2) . Neopterin levels were obtained in eight Avonex-treated and 18 Jumtab-treated patients. While the mean (SD) preinjection neopterin levels for Avonex 19 for both groups, following treatment, mean neopterin levels for the Avonex group rose consistently and approached the upper limit of the 95% confidence interval for the normal population (8.7 nmol/L), 19 while those for Jumtab patients remained statistically indistinguishable from pre-dose values (Table 2) . When the absolute change in neopterin levels was measured, the mean (SD) value for the Avonex-treated patients increased by 2.4 (2.2) nmol/L, while that for the Jumtabtreated patients increased by 0.7 (1.2) nmol/L (P=0.008). Moreover, the mean values shown in Figure 1 
adverse events
The most common adverse event for both formulations was the presence of flu-like symptoms, reported by 80.6% and 31.0% of Avonex-and Jumtab-treated patients, respectively (P=0.0004). In patients treated with Avonex, other adverse events reported by more than one patient included injectionsite reactions (n=5) and liver function abnormalities (n=2). The only adverse events seen with Jumtab other than flu-like symptoms were injection-site reactions and headache, which were reported by two patients each (Table 3) .
relapses
The results of a retrospective patient record review of MS relapses showed no significant differences between groups for any of the relapse-related endpoints, including the number of relapses, number of patients reporting relapses, duration of hospitalization per relapse, total duration of hospitalization per patient, duration of corticosteroid use per relapse, and total duration of corticosteroid use per patient (Table 4) .
Discussion
As the number of follow-on biologics being developed increases, it is critical to validate both the efficacy and safety of these new formulations, given the complexity of their manufacture and the risks presented by NAb formation. 3, 8 The MATRIX study was designed to provide a direct comparison between Avonex and a biosimilar, with a focus on assessing product safety in addition to measuring serum neopterin as a surrogate marker for immune activation. 
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The presence of NAbs has been associated with a more rapid progression of disability in RMS patients, a higher relapse rate, and an increase in the number of gadoliniumenhancing lesions on MRI. 20 These data indicate that the clinical efficacy of IFN beta-1a may depend on the absence of NAbs, and the degree of NAb induction is therefore an important aspect of a given drug's safety profile. Product heterogeneity is a known risk for the development of NAbs. 3 However, the relative risk of NAbs with Jumtab could not be addressed in this study because of the very low incidence of NAb induction for either IFN beta-1a formulation, compounded by the small number of patients that could be included in the final analysis.
MATRIX study enrollment was limited because of institutionally directed medication substitution at the pharmacy level, medication substitution based on local availability, and the resulting difficulty in verifying that all patients included in the study had been treated with a single IFN beta-1a formulation. Because of these enrollment concerns, the data here should be viewed as providing preliminary insights into the biological distinctions between these two compounds rather than offering definitive conclusions about the safety and efficacy of Jumtab versus Avonex. Further studies with substantially larger sample sizes are needed to conclusively establish the risk of developing NAbs subsequent to treatment with biosimilar IFN beta-1a.
Despite the low patient numbers, several important differences were seen in the biological activity of these two formulations. A secondary endpoint of the MATRIX study was to evaluate potential differences in the IFN biological activity of Jumtab relative to Avonex, using neopterin induction as a marker. 13, 19 Avonex but not Jumtab therapy was associated with robust elevations in neopterin levels, indicating significantly lower IFN biological activity with the biosimilar despite the amino acid homology between the products. It was also notable that baseline neopterin levels were higher in the Avonex-treated group, suggesting a consistent elevation of this biomarker due to IFN beta-1a activity. While these differences were not significant because of the low cohort sizes and the presence of outliers (Table 2) , they confirm prior studies demonstrating that Avonex is able to induce a robust biological response in most patients, 1,2 whereas this effect is less reliable for Jumtab. Neopterin levels in patients treated with Jumtab were lower, and may have been more likely to be suppressed than those in Avonex-treated cases, likely due to the low levels of active drug in the preparation. It is possible that the single Avonex-treated patient in whom suppression of neopterin induction was observed either did not inject the treatment or -due to natural variation in biological response -this patient's neopterin levels may simply be on the lower end of the expected range.
The differences in biomarkers cannot be attributed simply to the characteristics of the patient population. With the exception of the significantly younger age of the Avonextreated group and their somewhat higher EDSS score, there were no differences between the Avonex and Jumtab groups either in their baseline demographics or in clinical variables, including the number of relapses, the need for steroid therapy, or hospitalization (Table 4) .
Supportive evidence is also provided by the tolerability data from this study. Although flu-like symptoms are adverse events, they may also serve as indicators of an IFN's biological activity, since they may reflect activation of the immune system. Despite the comparable clinical efficacy of Avonex and Jumtab with respect to conventional parameters, including annual relapse rate, one of the notable findings of the MATRIX study was that significantly fewer patients reported flu-like symptoms on Jumtab than on Avonex. These data suggest reduced bioavailability of the biosimilar. The basis for this possible reduction in IFN beta-1a bioactivity has not been established, but it cannot readily be attributed to the presence of NAbs or reduced patient compliance.
The limitations of this study -due to the low patient recruitment, the non-randomized study design, and the retrospective nature of the analysis -make it impossible to reach solid conclusions about any substantial efficacy differences between Avonex and Jumtab. For example, because relapse-associated outcomes were assessed retrospectively based on cumulative data from 1 to 3 years prior to study enrollment, information regarding the specific time frame in which each relapse occurred was not available and calculation of an annualized relapse rate was not possible. Thus, the treatment differences identified in this study require confirmation in a larger prospective study that rigorously compares both the safety and the efficacy of Avonex and IFN beta-1a biosimilars. However, the data presented here provide preliminary evidence that the activity and possible efficacy of biosimilar therapies cannot be assumed to match those of the reference molecule and support the argument that switching patients from a parent formulation to a biosimilar product may have clinical consequences. 20 The rationale for requiring clinical trials of biosimilars prior to regulatory review is that, given the complexity of these biologic compounds, variations in manufacturing might lead to small variations in the protein that will produce differences in clinical efficacy. For example, the biosimilar IFN beta-1a generated in Chinese hamster ovary cells (Biferonex) was rejected by the European Committee for Medicinal Products for Human Use because of differences between the active molecule in Biferonex and that found in European Medicines Agency (EMA)-approved IFN beta-containing medicines. 21 Consistent with this finding, biosimilar IFN beta-1a products in general, including Jumtab, have been reported to vary considerably in their biological potency, with lower activity related to, among other factors, the presence of higher-molecular-weight aggregates of IFN beta-1a. 3 There are also reports of substantial variability in the chemical composition of batches of the same biosimilar IFN beta-1 products over time, and this variability might also contribute to the variable clinical efficacy seen here. 
Conclusion
These studies and the data presented here highlight the need for physicians seeking reliable clinical effects to ensure that the specific formulation their patients receive remains consistent. As regulatory guidelines for biosimilar development continue to evolve, 11 these findings indicate a strong basis, particularly in the European Union and North American countries, for strict regulation in the use of biosimilars to ensure that patients receive effective treatment.
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